ESG risk score 36.81
Environmental score -
Social score -
Governance score -
ESG risk category High
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
GeoVax Labs Inc
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol GOVX:xnas
Currency USD
NASDAQ (Small cap)
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -65.38%
1 year -93.62%
3 years -90.96%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -30.28
Volatility (30 days) 95.13%
Data provided by
Analyst consensus
Average rating Overweight
Rating Analysts
Buy
2
Overweight
0
Hold
1
Underweight
0
Sell
0
Target price 95
Implied return 6318.92%
Last updated 16-Apr-2026
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About GeoVax Labs Inc
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Sector Healthcare
Industry -
Market cap 0.004281004bn
Data provided by /
/ Frequently asked questions
To buy GeoVax Labs Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for GeoVax Labs Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for GeoVax Labs Inc is GOVX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
GeoVax Labs Inc has its primary listing on NASDAQ (Small cap). You can trade GeoVax Labs Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, GeoVax Labs Inc is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include GeoVax Labs Inc as part of a broader investment portfolio.